Canton Strategic Holdings Inc. (CNTN)
CNTN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CNTN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001861657 |
| SEC industry code | Finance Services |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-14 |
| Cash and burn | $37.2M cash; operating cash flow -$5.5M a quarter. | Report 2026-06-30 |
| Shares outstanding | 79,681,361 (2026-08-13); 4,635,251 a year earlier; 17,532,637 three years earlier. 3y figure adjusted for splits (1-for-375 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 2; latest 1-for-15 on 2024-05-28 | Source 2024-05-28 |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-03-03 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-01-15 |
| Auditor | Rosenberg Rich Baker Berman, P.A., Somerset, New Jersey, United States | PCAOB Form AP 2026-04-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $258K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $1.5M | -$19.3M | -$2.2M | $37.2M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2026-03-31 | Not filed | -$47.3M | -$7.6M | $41.5M | No debt tags | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2025 2025-12-31 | Not filed | -$29.4M | -$10.4M | $12.0M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | Not filed | -$2.1M | -$1.9M | $7.6M | $322K | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$1.9M | -$1.1M | $2.2M | $499K | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$2.5M | -$2.7M | $1.1M | $543K | Needs four quarters | 10-Q 2026-05-13 |
| Q4 2024 2024-12-31 | Not filed | -$3.8M | -$3.0M | $3.6M | No debt tags | Needs four quarters | 10-K 2026-03-31 |
| Q3 2024 2024-09-30 | Not filed | -$3.8M | -$2.9M | $4.8M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-03 |
| Latest annual report | 10-K | 2026-03-31 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-06-25 |
Source: SEC EDGAR submissions feed, 320 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.0% |
| 1 month | -15.3% |
| 3 months | -13.2% |
| Year to date | -43.6% |
| 1 year | -43.2% |
| From 52-week high | -68.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NTHI | NeOnc Technologies Holdings Inc. | $4.54 | -7.54% | $131.0M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| ALXO | ALX Oncology Holdings Inc. | $1.00 | -3.85% | $124.9M |
| AKBA | Akebia Therapeutics Inc. | $0.4486 | -5.40% | $124.6M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| SPRB | Spruce Biosciences Inc. | $42.25 | -2.45% | $121.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier